Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells
in patients with uremia-associated urothelial carcinoma.
Secondary Objective: To evaluate the general safety and tolerability of oral lycopene 30 mg
per day for 12 weeks in uremic patients.